J Korean Med Assoc Search

CLOSE


J Korean Med Assoc > Volume 55(9); 2012 > Article
Park: Policy for drug safety and its impact on the patient safety

References

1. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;2:1358.

2. Waxman HA. The lessons of Vioxx-drug safety and sales. N Engl J Med 2005;352:2576-2578.

3. World Health Organization. The importance of pharmacovigilance 2002.

4. Wood SF, Perosino KL. Increasing transparency at the FDA: the impact of the FDA Amendments Act of 2007. Public Health Rep 2008;123:527-530.

5. Permanand G, Mossialos E, McKee M. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance. Clin Med 2006;6:87-90.

6. U.S. Food and Drug Administration. The Food and Drug Administration Amendments Act of 2007 (FDAAA) 2007.

7. European Commission. Volume 9A of the Rule Governing Medicinal Products in the European Union ; Guidelines on Pharmacovigilance for Medicinal Products for Human Use 2008.

8. American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm 1993;50:305-314.



ABOUT
ARTICLE CATEGORY

Browse all articles >

ARCHIVES
FOR CONTRIBUTORS
Editorial Office
37 Ichon-ro 46-gil, Yongsan-gu, Seoul
Tel: +82-2-6350-6562    Fax: +82-2-792-5208    E-mail: jkmamaster@gmail.com                

Copyright © 2024 by Korean Medical Association.

Developed in M2PI

Close layer
prev next